Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development.

Oxid Med Cell Longev · 2020 · PMC7240663 · PMID 32454942

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A randomized proof-of-concept study indicated that secukinumab reduced lesion activity in MS patients and showed a trend toward reduced relapse rates [ 31 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.